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Summary Drug resistance is generally considered to be a major impediment to successful cancer chemotherapy, yet it is generally not
possible to predict the degree or timing of the emergence of tumour resistance in most chemotherapy protocols. Recent developments with
the single-cell gel electrophoresis or 'comet' assay for DNA damage atthe single-cell level suggestthatthistechnique might provide a method
for identifying and potentially monitoring tumour cell responsiveness to many anti-cancer agents in situ. In principle, this assay could be
applied to any accessible tumour being treated with chemotherapeutic agents that cause overt DNA damage. We have investigated that
supposition using several rodent and human tumourcell lines exhibiting a spectrum of resistance tothe DNA strand-breaking drug, etoposide.
By assessing cells grown as monolayers, spheroids and xenografted tumours in immunodeficient mice, we found that the comet assay can
provide not only an index of sensitivity to etoposide, but, additionally, can demonstrate the efficacy (or lack thereof) of multidrug resistance
(MDR) reversing agents for cells in vitro, and tumours in vivo.
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Drug resistance is generally considered to be the major impedi-
ment to success in modem cancer chemotherapy. Considerable
effort has thus been expended on identifying those tumours likely
to be, or to become, resistant to the chemotherapy protocol of
choice (Bellamy, 1992; Sevin et al, 1994; Kaye, 1995). Generally,
such 'chemosensitivity testing' relies on comparative or quantita-
tive estimates ofcell growth in tissue culture, in the presence of a
range oftest concentrations ofthe drugs ofchoice. Although it can
be argued that many such assays have demonstrated a workable
level of accuracy (Von Hoff, 1990), the practical problems of
processing tumour biopsies, waiting for assay results and ulti-
mately planning therapy on the basis of such studies render most
of these approaches less than satisfactory (Von Hoff, 1990; Von
Hoffet al, 1991).
In addition to the practical problems with in vitro chemosensi-
tivity testing just listed, other considerations include whether any
single biopsy is truly representative, whether response in vitro
necessarily reflects that in situ, and whether the obligatory 'aver-
aging' for the biopsied cell population as a whole overshadows
small, but significantly resistant subpopulations. It would seem
that measuring response in situ could be preferable, particularly if
multiple assays could be performed throughout therapy, and if
information were forthcoming not only on mean or median
response but also the presence of unusually resistant subpopula-
tions. In principle, the single-cell gel microelectrophoresis tech-
nique, or 'comet' assay, encompasses all these capabilities (Ostling
and Johanson, 1984; Olive et al, 1990; Fairbaim et al, 1995).
Unlike other approaches, the comet assay is single cell based,
and therefore provides information not only on the overall
response of the sample, but also on the heterogeneity inherent
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within a particular specimen (Olive et al, 1990; 1993b). Sampling
can be envisaged as either an advantage or disadvantage: only a
few thousand cells can realistically be processed, allowing the
assay to be performed with tumour cells obtained from procedures
as minimally invasive as fine-needle aspirate biopsies (Olive et al,
1993b, d; Fairbaim et al, 1995). Conversely, however, the reduced
sample size potentially limits representativeness. As the assay can
be modified to detect DNA single-strand breaks, double-strand
breaks, cross-links and even other forms of DNA damage, it is
potentially applicable to a wide variety of chemotherapy agents
(Fairbaim et al, 1995). Naturally, the comet assay must be
performed at times when measurable damage persists within the
tumour. In addition, it is desirable that the assessed DNA damage
bears some relevance to the desired end point, that is, tumour cell
kill by the chemotherapy agent(s).
In this study, we investigated rodent and human tumour cell
lines that show different degrees of 'multidrug' resistance, in
which the cells were cultured in vitro or grown as xenografted
tumours in vivo. The experimental drug of choice was etoposide,
as it is anefficient DNA strandbreakerin proliferating cells (Olive
et al, 1993a, d), and is a well-known substrate for p-glycoprotein
(P-gp) modulated drug resistance (Pastan and Gottesman, 1991;
Rowinsky, 1991). In fact, the use ofetoposide in solid tumours or
spheroids with significant numbers ofquiescent cells is a particu-
larly stringent test of the predictivity of the comet assay, as
reducing the fraction of responding cells necessarily decreases
assay sensitivity (but still reflects, in a qualitative sense, tumour
response to the agent).
To further assess the predictive potential of the comet assay, we
examined two known modulators of P-gp function, verapamil and
dipyridamole(Clynes etal, 1993;Leyland-Jones etal, 1993; Ayeshet
al, 1996), for their capacity to increase etoposide damage. We also
examined the effects ofdipyridamole in vivo, to determine whether
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activity of even a relatively inefficient P-gp modulator could be
demonstrated by the comet assay. As both the utility ofthe assay for
identifying chemoresistance, and for indicating activity of modu-
lating agents provedtobedemonstrable, wealsoexaminedthepoten-
tial sensitivity ofthe assay foridentifying subsets ofresistant cells.
MATERIALS AND METHODS
Most in vitro studies were performed with Chinese hamster V79
fibroblasts, maintained in tissue culture in Eagle's minimal essen-
tial medium (MEM) supplemented with 10% fetal bovine serum
(FBS). Two sublines ofthis strain were developed locally for resis-
tance studies: the line designated VVPR" which was isolated by
continuous growth in escalating concentrations of etoposide, and
theVADR subline, which was similarly produced using doxorubicin
as the selection agent. The doxorubicin-resistant line was routinely
passaged in drug-containing medium to maintain the levels of
resistance. We also include data from two human tumour cell lines
(obtained from ATCC), the WiDr colon adenocarcinoma and the
U87 glioblastoma. These human cell lines were cultured in MEM
+ 10% FBS. The WiDr line spontaneously forms multicell spher-
oids when grown in stirred suspension cultures; our protocols for
spheroid growth and assay have previously been described in detail
(Sutherland and Durand, 1976; 1984; Olive and Durand, 1994).
The clinical formulation of etoposide marketed by Bristol
Myers-Squibb was used; verapamil and dipyridamole were
purchased from Sigma Chemicals (St Louis, MI, USA). Etoposide
was diluted into the culture medium or injected i.p. into animals as
required; verapamil and dipyridamole were prepared as stock
solutions of 5-10 mm in absolute ethanol or 100% dimethyl
sulphoxide (DMSO), respectively, and added to culture media or
injected i.p. into animals as required from those stock solutions.
The alkaline comet assay was used for measurement of DNA
single-strand breaks (Olive et al, 1990). Cells were collected in a
suspension of about 2 x 104 cells ml' and maintained at 4°C.
Aliquots of0.5 ml were then placed in a 5-ml disposable tube, and
1.5 ml of 1% low gelling temperature agarose (Sigma type VII
prepared in distilled water and held at 40°C) added. From this,
1.5 ml was quickly pipetted onto a half-frosted microscope slide
and allowed to gel for about 1 min on a cold surface. Slides were
then carefully submersed for 1 h in an alkaline lysis solution
containing 1.0 M sodium chloride, 0.03 M sodium hydroxide and
0.2% n-lauroyl-sarcosine, maintaining them in a horizontal posi-
tion. This was followed by a 1-h wash in two rinses of 0.03 M
sodium hydroxide plus 2.0 mm EDTA. Slides were then elec-
trophoresed at 0.6 V cm-1 for 25 min in a fresh solution of 0.03 M
sodium hydroxide and 2.0 mm EDTA in a horizontal chamber,
rinsed in water and stained for 20 min in 2.5 ,ug ml-1 propidium
iodide (see Olive et al, 1992 for additional details). All chemicals
were purchased from Sigma Chemical (St Louis, MI, USA).
At least 200 individual cells (comets) per sample were viewed
using a Zeiss epifluorescence microscope attached to an intensi-
fied solid state CCD camera and image analysis system (Olive et
al, 1990). DNA damage was automatically determined by locally
developed software; the reported 'tail moment' is the product of
the fraction ofthe DNA in the comet tail, and the distance between
the centres of mass of the head and tail distributions (Olive et al,
1990; 1992; 1993d). Each 'comet' was individually analysed
using the fitting routines we developed, and the reported values are
the averages for the entire cell population processed for each
experimental condition.
U'
0)
C. 0
Cu
0
IL) C
0 CD
0
0
12'
A~~~~ 0
0.1 E
0 E 6
0.01 3-
0
0.1 1 10 100 0.1 1 10 100
Etoposide concentration (,ug mr1)
Figure 1 Toxicity of 0.5-h exposures to etoposide for V79 parent (0) or
etoposide-resistant VVPR (U) cells as reflected by clonogenicity (A) or DNA
damage (B). Note that the comet assay for DNA damage was responsive
over the same drug dose range in which cytotoxicity occurred, and that a
similar degree of resistance was seen for the resistant cells
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Figure 2 Use of the comet assay to illustrate the response of parent V79
cells and two resistant sublines to 1-h exposures to etoposide as a single
agent (0) or in the presence of 10gM verapamil (-) or 10gM dipyridamole
(*). Note the progressive increase in resistance from A to C, as indicated by
the reduced response and the substantial differences in administered doses.
The modulators were, however, effective in all cell lines. Uncertainties show
s.e.m. for a minimum of three independent experiments
The human tumour lines were grown as xenografts in CB-
17/SCID mice (bred in-house, and used at 6-8 weeks) in which
tumours were produced by injection of 106 tumour cells subcuta-
neously on the sacral region of the back. For all studies reported
here, the entire tumour (approximately 8-10 mm diameter) was
excised after treatment, and reduced to a single-cell suspension by
finely mincing the tumour and filtering through 30-,m nylon
mesh. Care was taken to process the tumour cells as rapidly as
possible to minimize damage repair during the assay interval.
Greater cell yields per tumour, and fewer aggregates in the single-
cell suspensions couldbe produced by subsequentenzymatic treat-
ment of the minced tumours. However, as only relatively small
numbers of cells were required for the comet assay, and as repair
of damage during extended processing times cannot easily be
distinguished from modulation of initial damage, we chose to use
mechanical dissociation alone.
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Figure 3 Response of WiDr cells in vitro to 2-h exposures to etoposide as
single agent (0) or in the presence of verapamil (U) or dipyridamole (*).
Each modulator was used at 10 gM (A) and 20 gM (B). Uncertainties show
s.e.m. for a minimum of three independent experiments
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Figure 5 DNA damage produced by etoposide in human U87 glioblastoma
cells grown in vitro (A) or as xenografts in SCID mice (B). The U87 cells were
moderately resistant to 10 jg ml-1 etoposide for 2 h as monolayers (compare
A with Figure 2). As tumours, however, similar responses were observed
irrespective of whether 50 jg g1 etoposide was administered alone (0) or
with 50 jg g-' dipyridamole (*). The DNA damage seen in untreated
tumours, or with dipyridamole injection alone is shown (K), and uncertainties
again represent s.e.m. for a minimum of three independent experiments
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Figure 4 DNA damage produced by 50 jg g9- etoposide in human WiDr
carcinomas xenografted in SCID mice (0) and its modulation by
simultaneous administration of 50 jg g-1 dipyridamole (*). Note that
dipyrdamole clearly increased the amount of DNA damage in the tumour
cells, particularly when assessed at early times after administration. For
reference, the DNA damage seen in untreated tumours (0-h exposure) or
with dipyridamole injection alone is also shown (O). Uncertainties again
represent s.e.m. for a minimum of three independent experiments
RESULTS
The use of the comet assay as a predictor for drug sensitivity is
illustrated in Figure 1, in which the response ofmonolayers ofthe
V79 parent cell line and the etoposide-resistant VVPR daughter line
were intercompared using conventional clonogenicity or the comet
assay 'tail moment' as the experimental end point. In both cases,
about tenfold higher drug concentrations produced a given level of
damage in theVVPR cells. Additionally, and perhaps of even greater
importance in terms ofpredictive assays, both end points produced
responses over the same range ofdrug concentrations.
The response of the parent V79 cell line, the VVPR line, and an
even more MDR proficient line (VADR, developed by growth in
escalating concentrations ofdoxorubicin) was compared in Figure
2. Note that the vertical axis (DNA damage expressed as tail
moment) was kept constant for all panels; greater etoposide
exposures were, however, required to produce similar degrees of
response for the VVPR vs parent cell lines, and much higher drug
concentrations produced only minimal DNA damage in the highly
resistant VADR cell line. In all cases, both verapamil and dipyri-
damole enhanced the cellular response to etoposide; equal damage
was produced by approximately a twofold reduction in drug
concentration. It should be noted that the parental V79 cell line
expresses low, but detectable, levels of P-gp with immunohisto-
chemical analyses (data not shown).
The WiDr colon adenocarcinoma cell line, like many human
tumour cells, is relatively resistant to etoposide and other P-gp
substrates (Figure 3), and shows moderate levels of staining with
anti-P-gp antibodies. Growth of the cells as three-dimensional
spheroids (with concomitant changes in growth fraction and drug
availability) produced an additional level of resistance (Figure
3B). Not only was the responsiveness of the cells in the intact
spheroid quantitatively changed, but also the curve was qualita-
tively different: a plateau in drug efficacy was seen even for very
high doses. This response is consistent with previous results in
WiDr spheroids and xenografts examined for DNA damage after
exposure to etoposide; a significant fraction of the cells failed to
show DNA damage in the comet assay, and these presumably non-
cycling cells were localized to the inner regions ofWiDr spheroids
(Olive and Bandth, 1992). Both verapamil and dipyridamole were
effective modulators in the monolayer and spheroid cultures, and
in the monolayers both modulators were at least as effective as in
the rodent cell lines in Figure 2.
Figure 4 shows the response ofthe WiDr cell line when grown as
a xenografted tumour in SCID mice. Unlike the previous figures,
the horizontal axis in this case reflects time after administration of
etoposide as a single agent, or after simultaneous injection of
etoposide and the modulator dipyridamole. Two features are of
note: even in vivo, dipyridamole demonstrably acted as a modu-
lator, increasing the damage at all observation times. Additionally,
and as would be expected, the response curves reflect the sum of
many factors: damage induction by circulating drug, pharmacolog-
ical clearance of the etoposide, and repair of the drug-induced
DNA single-strand breaks. For reference, the 'damage' produced
by dipyridamole alone is indicated for the 2-h exposure; this point
was not significantly different from that seen for untreated
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Figure 6 A reconstruction experiment showing the sensitivity of the comet assay for detecting small populations of resistant cells. The VVPR parent and V79
(etoposide-resistant) cell lines, having the responses to 1-h exposures to 2 gg ml-' etoposide shown in A and B, were mixed in various proportions and the
resulting comet distributions of D-H analysed by determining the fraction of comets with tail moments less than the arbitrary value of 5.0 (C). Note that very
small populations of resistant cells could be resolved in this manner
tumours, as a quite high level of cell damage is typically seen
whenever there is a significant dying cell fraction (necrotic
regions), and/or tissue damage from the assay procedure itself.
Use of the comet assay as a predictor for chemosensitivity was
also evaluated in another human tumour cell line, the U87
glioblastoma, grown as both monolayers and xenografts. The U87
cells were somewhat more sensitive to etoposide than the WiDr
cell line (Figure 5A). When grown as xenografts, a qualitatively
different response was however observed: no additional damage
was produced by addition of the modulator. Consequently, the
comet assay appears to be capable of distinguishing between
tumours that do (Figure 4) or do not (Figure 5B) respond to an
MDR modulator.
The data presented have addressed only the ability of the comet
assay to indicate the relative resistance of the target cells to etopo-
side, without providing any direct evidence of heterogeneity
within the various populations of cells assessed. As argued in the
introduction, the ability to quantify heterogeneity remains one of
the key features of the comet assay, and the validity of this
approach has previously been shown for WiDr spheroids exposed
to etoposide (Olive and Banath, 1992).
Heterogeneity is, however, inherent within any cell population,
and particularly in solid tumours containing quiescent (etoposide-
resistant) cells. To assess the underlying cause and impact of
heterogeneity, definitive studies are most easily performed in
,reconstruction' experiments using known mixtures of cell popula-
tions with definable degrees of resistance. That approach is shown
in Figure 6, in which different proportions of the V79 parent and
VVPR (etoposide-resistant) cell lines were assessed. Figure 6A and
B shows histograms indicating the distribution of damage induced
in the resistant and sensitive cell lines, respectively, whereas
Figure 6D-6H shows the response of a population composed of
increasing percentages of drug resistant cells. A good correlation
between the observed and expected fraction of resistant cells (in
which observed resistance was based on an arbitrary cut-off of a
tail moment value of 5), is shown in C. These results suggest that
as few as 1-2% resistant cells can be resolved by the standard alka-
line comet assay even in a population only tenfold more resistant.
DISCUSSION
Our results show that the alkaline comet assay can provide an
index of tumour resistance to etoposide in situ, and further, that the
ability of MDR-reversing agents to increase tumour response can
be assessed. Given that the comet assay can be performed with
very small samples, including those obtained with fine-needle
aspirate biopsies, we suggest that adaptations of this assay might
be highly beneficial for assessing the resistance of appropriate
human tumours during chemotherapy.
As has been suggested throughout this manuscript, there are a
number of inherent limitations to the use of the comet assay as a
predictive assay. Two are paramount: only drugs that produce
measurable quantities of DNA damage can be assessed, and such
assessments can only be made in accessible tumours. Given,
British Journal of Cancer (1998) 77(3), 412-416
25
0)
a)
E
0
a)
.0
E
z
v In
a)
E
0
E
0El
75_
50_
25
00
25
20
15
10
5
0
D
E
F
G
H
- .
. Cancer Research Campaign 1998416 P Huang etal
however, that adequate samples can often be obtained with fine-
needle aspirate biopsies, it would seem that this type of assay
could have considerable impact in the clinic. Our intent in this
work was to demonstrate proof of principle, rather than high-
lighting a particular treatment regimen or modulator. In clinical
practice, single drug administrations are seldom used; that should
not be aproblem in terms ofevaluating the assay, provided (again)
that DNA damage is produced by the combination chemotherapy.
Such damage is clearly produced by many common chemothera-
peutic drugs, including most alkylating agents and inhibitors of
topoisomerases I or II. Interestingly, the ability ofthe comet assay
to identify and quantify apoptotic cells (Olive et al, 1993c)
suggests a further extension ofthe methodology.
There is obviously considerable current interest in development
ofmore active, higher potency modulators ofmultidrug resistance.
Our decision to use dipyridamole for the xenograft studies
reported here was based on the presumption that it would
adequately serve as a trial agent, and it was one that could easily
be administered at required doses without the complication of
producing additional damage as a single agent.
From a more practical point of view, it is noteworthy that the
comet assay produces quantifiable data that can be fairly easily
translated from system to system. As has been shown here, the tail
moment measured using the comet assay is qualitatively and quan-
titatively related to the cytotoxicity measured by growth or clono-
genicity end points (with the proviso, of course, that all cells are
proliferating or conversely, that the growth fraction is known).
This suggests that the response of tumour cells in situ could be
directly estimated if peak or area under the curve estimates of
tumour exposure to the chemotherapeutic agent were available.
Even in the typical case in which such data might not be available,
comparison of data from any particular tumour with a historical
database generated by a particular laboratory would presumably
indicate whether a particular tumour was among the most or least
responsive for that particular site and stage. Further, the ability to
perform sequential or multiple samples with fine-needle aspirates
may lead to modulator studies in which a given tumour could act
as its own control.
In summary, our data show that the comet assay appears to have
significant promise as a method ofdetermining the responsiveness
ofbiopsy-accessible tumours to combination chemotherapy in situ.
Additionally, the measurement seems to have sufficient repro-
ducibility to allow modulator orchemosensitization studies as well.
Clinical assessments ofthis methodology now seem indicated.
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